Four buyouts (and one rumor that didn’t materialize); Isomorphic Labs’ first pharma deals; A CAR-T IPO; #JPM24 highlights; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

From what I’ve heard from my col­leagues in San Fran­cis­co, it’s been a busy but fruit­ful JPM con­fer­ence for End­points. Thank you to every­one who joined our events or shared your in­sights with us — we’ll see you next year!

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.